Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451

GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV infection. Key preclinical properties of GS-9451, including in vitro antiviral activity, selectivity, cross-resistance, and combination activity, as well as pharmacokinetic...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yang, Huiling, Robinson, Margaret, Corsa, Amoreena C., Peng, Betty, Cheng, Guofeng, Tian, Yang, Wang, Yujin, Pakdaman, Rowchanak, Shen, Marian, Qi, Xiaoping, Mo, Hongmei, Tay, Chin, Krawczyk, Steve, Sheng, X. Christopher, Kim, Choung U., Yang, Chris, Delaney, William E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2014
Aiheet:
Antiviral Agents
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3910871/
https://ncbi.nlm.nih.gov/pubmed/23939899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00487-13
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia